Blueprint Medicines Corporation (BPMC) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Cambridge, MA, アメリカ. 現CEOは Kathryn Haviland.
BPMC を有する IPO日 2015-04-30, 682 名の正社員, に上場 NASDAQ Global Select, 時価総額 $8.36B.
Blueprint Medicines Corporation is a precision therapy company that develops targeted medicines for genomically defined cancers and blood disorders globally. The company's marketed and pipeline products include AYVAKIT and BLU-263 for systemic mastocytosis and mast cell disorders, GAVRETO for RET fusion-positive cancers, Fisogatinib for hepatocellular carcinoma, and several investigational therapies targeting EGFR mutations in non-small-cell lung cancer, as well as rare genetic disorders. Blueprint maintains strategic collaborations with leading pharmaceutical partners including Genentech, Roche, CStone Pharmaceuticals, and Zai Lab to advance its precision medicine pipeline. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company is committed to delivering transformative treatments for patients with serious diseases driven by specific genetic alterations.
